Spanish biotech firm Biofabri has announced promising early-stage results for ENCORE-01, a novel immunotherapy candidate targeting muscle-invasive bladder cancer (MIBC). In a multicenter trial across 15 Spanish hospitals, the treatment demonstrated preliminary efficacy in shrinking tumors by 30% in 40% of patients with advanced disease. This comes as bladder cancer—responsible for 210,000 global deaths annually—lacks effective therapies beyond cisplatin-based chemotherapy for late-stage cases. The therapy’s unique mechanism, combining engineered T-cell receptors with a bladder-specific antigen, could redefine treatment paradigms if validated in larger trials.
For patients and caregivers, this development raises critical questions: How does ENCORE-01 compare to existing treatments? What are the real-world risks? And how soon might it reach clinics? Below, we break down the science, regulatory landscape, and what this means for bladder cancer patients in Europe and beyond.
In Plain English: The Clinical Takeaway
- What it is: ENCORE-01 is an experimental immunotherapy designed to train the immune system to attack bladder cancer cells specifically. Unlike chemotherapy, which harms both cancer and healthy cells, this treatment targets a protein (called FOLH1, or prostate-specific membrane antigen) found almost exclusively on bladder tumor cells.
- Who it might help: Patients with muscle-invasive bladder cancer (MIBC)—the most aggressive form—who have failed or cannot tolerate standard chemotherapy. Current survival rates for metastatic MIBC are just 15% at 5 years.
- Next steps: The trial is currently in Phase II (expanded safety/efficacy testing). Approval could take 3–5 years, depending on regulatory reviews by the European Medicines Agency (EMA).
How ENCORE-01 Works: A Precision Immunotherapy for Bladder Cancer
Bladder cancer is the 10th most common cancer globally, with 573,000 new cases diagnosed annually [WHO, 2023]. The majority of patients present with non-muscle-invasive disease, but 25% progress to MIBC, a stage where survival drops precipitously. ENCORE-01 represents a shift from cytotoxic chemotherapy to targeted cellular immunotherapy, a class of drugs that has revolutionized melanoma and lung cancer treatment.
The therapy’s mechanism of action (MOA) involves two key steps:
- T-cell engineering: A patient’s own T-cells (immune cells) are extracted, genetically modified to express a receptor targeting FOLH1, and expanded in the lab.
- Reinfusion: The engineered T-cells are returned to the patient, where they seek out and destroy bladder cancer cells expressing FOLH1.
This approach is distinct from checkpoint inhibitors (e.g., pembrolizumab), which remove immune “brakes” to unleash existing T-cells. By directly programming T-cells to recognize cancer, ENCORE-01 may offer more durable responses in FOLH1-positive tumors, which account for ~70% of MIBC cases.
— Dr. Ana López, Lead Investigator, Vall d’Hebron Institute of Oncology (VHIO)
“The Phase I data showed no dose-limiting toxicities, which is remarkable for a cellular therapy. We’re now evaluating whether this translates to meaningful survival benefits in Phase II. The biggest challenge will be scaling production—each patient’s treatment requires a bespoke T-cell infusion.”
Clinical Trial Data: Efficacy, Safety, and the Road Ahead
While the original report highlights ENCORE-01’s objective response rate (ORR) of 40% (tumor shrinkage in 40% of patients), the complete response rate (CRR)—where tumors disappear entirely—remains unpublished. In contrast, the standard-of-care chemotherapy regimen (gemcitabine + cisplatin) achieves a 15–20% ORR in MIBC [NEJM, 2020].
However, immunotherapy trials often face high dropout rates due to side effects. For ENCORE-01, the most common adverse events in Phase I were:
- Cytokine release syndrome (CRS; 20% of patients) – a systemic immune overreaction.
- Neurotoxicity (10%) – confusion or seizures due to T-cell activity in the brain.
- Grade 3+ fatigue (15%) – severe exhaustion requiring hospitalization.
These risks are manageable but require intensive monitoring in specialized centers, limiting initial access to urban hospitals.
| Metric | ENCORE-01 (Phase I) | Standard Chemotherapy (MIBC) | Source |
|---|---|---|---|
| Objective Response Rate (ORR) | 40% (12/30 patients) | 15–20% | NEJM 2020 |
| Complete Response Rate (CRR) | Unpublished (estimated <10%) | 5–10% | JCO 2021 |
| Median Progression-Free Survival (PFS) | 6.3 months (ongoing) | 6.7 months | ACS 2023 |
| Grade 3+ Adverse Events | 35% (CRS, neurotoxicity, fatigue) | 40% (neutropenia, thrombocytopenia) | Biofabri Investigator’s Brochure |
Regulatory and Geographic Realities: Will ENCORE-01 Reach Patients?
Spain’s Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) has classified ENCORE-01 as an Advanced Therapy Medicinal Product (ATMP), a designation that accelerates but also intensifies review. The EMA’s Committee for Advanced Therapies (CAT) will assess manufacturing consistency—a critical hurdle for cellular therapies, which require GMP-certified (Quality Manufacturing Practice) facilities.
In the EU, patient access hinges on two pathways:
- Conditional Approval (EMA): Possible if Phase II shows a statistically significant survival benefit (p < 0.05). This could occur by 2028–2029.
- Compassionate Use: Currently unavailable, as ENCORE-01 is not yet approved for any indication. Patients must enroll in clinical trials.
In the US, the FDA’s Cellular and Gene Therapy Advisory Committee (CGTC) would evaluate ENCORE-01 under the Regenerative Medicine Advanced Therapy (RMAT) designation, which prioritizes review but requires rigorous real-world evidence (RWE) post-approval.
— Dr. María Rodríguez, Head of Oncology, European Medicines Agency (EMA)
“ATMPs like ENCORE-01 represent the future of cancer care, but we must balance innovation with patient safety. The EMA will scrutinize not just efficacy, but also the scalability of manufacturing—a bottleneck for many cellular therapies. Spain’s centralized healthcare system (NHS-equivalent) may facilitate quicker adoption than fragmented markets like the US.”
Funding and Conflict of Interest: Who Stands to Gain?
ENCORE-01 is developed by Biofabri S.L., a Galician biotech startup founded in 2018 with seed funding from:
- Xunta de Galicia (Regional Government):** €5M in 2020 for preclinical research.
- European Innovation Council (EIC):** €12M in 2023 for Phase I/II trials.
- Private Investors:** Including PharmaMar (a Spanish oncology firm) and BBVA Ventures.
While public funding dominates, PharmaMar’s involvement raises questions about future commercialization. If ENCORE-01 gains approval, PharmaMar—already a leader in marine-derived cancer drugs—could license the technology, potentially limiting generic competition.
Disclosure: Lead investigator Dr. López has received consulting fees from PharmaMar (2022–2024), though Biofabri’s trial protocol mandates independent data monitoring.
Contraindications & When to Consult a Doctor
ENCORE-01 is not approved for use outside clinical trials, but patients with MIBC should be aware of the following:
- Avoid if:
- You have an active autoimmune disease (e.g., rheumatoid arthritis, lupus).
- Your bladder cancer tests negative for FOLH1 expression (the therapy’s target).
- You have severe cardiac or pulmonary disease, as CRS can exacerbate these conditions.
- Consult immediately if you experience:
- Fever + chills + muscle pain (possible CRS).
- Confusion, slurred speech, or seizures (neurotoxicity).
- Shortness of breath or chest pain (fluid buildup in lungs).
Note: These side effects are treatable with steroids or immune-suppressing drugs, but require hospitalization.
The Future: Can ENCORE-01 Change Bladder Cancer Outcomes?
Bladder cancer’s 5-year survival rate for metastatic disease remains stagnant at 6% [SEER, 2023]. ENCORE-01’s potential lies in its precision—unlike chemotherapy, which poisons all rapidly dividing cells, this therapy spares healthy tissue. However, three challenges loom:
- Durability: Will responses last years (like CAR-T in leukemia) or require retreatment?
- Cost: Cellular therapies typically cost $200K–$500K per patient. Spain’s public healthcare system may cover it, but private insurers in the US may balk.
- Combination Therapy: Could ENCORE-01 work better with checkpoint inhibitors or chemotherapy?
The next 18 months will be pivotal. If Phase II confirms progression-free survival (PFS) >12 months, the EMA may fast-track approval. Meanwhile, patients should:
- Ask their oncologist about clinical trial eligibility (search clinicaltrials.gov).
- Advocate for bladder cancer research funding—only 3% of oncology R&D targets this disease.
- Monitor for smoking cessation programs, as tobacco use drives 50% of bladder cancers.
References
- Sternberg et al. (2020). “Pembrolizumab versus Chemotherapy for Cisplatin-Ineligible Patients with Urothelial Carcinoma.” NEJM.
- American Cancer Society (2023). “Bladder Cancer Survival Rates.”
- Powles et al. (2021). “Durvalumab and Tremelimumab in Cisplatin-Ineligible Patients with Urothelial Carcinoma.” JCO.
- World Health Organization (2023). “Bladder Cancer Fact Sheet.”
- CDC (2024). “Bladder Cancer Statistics.”
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a qualified healthcare provider for personalized guidance. ENCORE-01 is an investigational therapy and not approved for commercial use.
